Previous 10 | Next 10 |
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarter New clinical data for palazestrant (OP-1250) in combination with CDK4/6 inhibitors to be presented at the 2023 San Antonio Breast...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...
2023-11-06 15:15:53 ET More on Olema Pharmaceuticals Olema: Two-Pronged Approach To Treat Breast Cancer Patients Olema: Contrarian Small Cap Oncology Biotech (Reiterating Buy) Olema Pharmaceuticals up 6% on $180M financing Seeking Alpha’s Quant Rating ...
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s ...
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis of 49 second- and third-line patients, the median PFS was 7.2 months with a CBR of 48%; t...
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved -4.55% on the day to $12.05. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapi...
Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023 Olema will host an investor conference call at 8:00 a.m. ET on October 23, 2023 SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (...
2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women...
News, Short Squeeze, Breakout and More Instantly...
Olema Pharmaceuticals Inc. Company Name:
OLMA Stock Symbol:
NASDAQ Market:
Olema Pharmaceuticals Inc. Website:
2024-06-13 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 15:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for OLMA on June 4, 2024 02:10PM ET. The previous analyst recommendation was Outperform. OLMA was trading at $14.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is one of today's top gainers. The company's shares have moved 17.73% on the day to $13.84. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's ...